Raludotatug deruxtecan
R-DXd (DS-6000)
PHASE2
Drug Profile
ModalityADC
RouteIV
Therapy AreaOncology
Formulations[]
Mechanism: CDH6-directed (DXd payload)
Expert: First-in-class CDH6-directed ADC with DXd payload. CDH6 overexpression in platinum-resistant ovarian cancer and renal cell carcinoma provides novel therapeutic target.
Everyday: An antibody-drug conjugate that targets CDH6 (Cadherin 6), a protein found on ovarian and kidney cancers.
Targets: ["CDH6"]
Programs (2)
| Indication | Stage | Key Study | Regional Status |
|---|
| PROC | PHASE2 | DS-6000-A-J102 | [] |
| RCC | PHASE1 | — | [] |
Upcoming Catalysts (1)
R-DXd - Platinum-Resistant Ovarian - Ph2/3 - Updates (REJOICE-Ovarian01)
2026
Notes
First-in-class CDH6-directed ADC. Phase 2 in platinum-resistant ovarian cancer (46% ORR, 7.9mo PFS). Also in renal cell carcinoma. Earliest stage in the 5DXd portfolio.
Data from Supabase · Updated 2026-03-24